Beacon Biosignals key facts
as of Oct 2026- Developer of an artificial intelligence-based neurotechnology platform designed for accelerating the clinical development of therapeutics targeting brain health.
- Beacon Biosignals is valued at approximately $334.0M as of Oct 2026, set at its later-stage round, Oct 2025; nothing has traded since, per PrivateMarketView’s mark.
- It has raised $126.9M across 2 recorded rounds; the latest was Later Stage VC ($103.3M) in Oct 2025.
- Notable investors include Alumni Ventures, General Catalyst, GV, Samsung NEXT Ventures, Inovia Capital — 20 tracked in total.
- 2 investment vehicles were formed to buy Beacon Biosignals shares in the last 12 months, reporting $974K sold to 39 investors, per SEC Form D filings.
- Beacon Biosignals has filed 2 Form Ds with the SEC since 2021, most recently Apr 2026 ($103.3M sold to 43 investors).
- Status: Privately Held (backing).
Valued at $334.0M at its later-stage round, Oct 2025. Nothing has traded since.
- ·The complete investor list: 20 names
- ·Watch Beacon Biosignals: the Monday email on marks, rounds and moves
Beacon Biosignals funding rounds
2 roundsVehicles formed to buy Beacon Biosignals shares
secondary demand · SEC Form D filingsIn the last 12 months, 2 investment vehicles were formed to buy Beacon Biosignals shares, reporting $974K sold to 39 investors across 2 sponsors. Most recent filing Feb 2026.
Membership and data by Private Market View
Who backs Beacon Biosignals
20+Membership and data by Private Market View
Beacon Biosignals valuation
Beacon Biosignals was valued at $334 million at its later-stage round in Oct 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.
How much has Beacon Biosignals raised?
Beacon Biosignals has raised $127 million across 2 recorded rounds since 2021. The largest was a $29.9 million early-stage round in Sep 2021; the most recent was a $103 million later-stage round in Oct 2025.
Beacon Biosignals has filed 2 Form Ds with the SEC since 2021, most recently in Apr 2026 ($103 million sold to 43 investors).
Institutional holders and vehicles
In the last 12 months, 2 investment vehicles were formed to buy Beacon Biosignals shares, reporting $974,000 sold to 39 investors across 2 sponsors, per SEC Form D filings (most recent Feb 2026).
Beacon Biosignals investors
20 investors are on record for Beacon Biosignals, including Alumni Ventures, General Catalyst, GV and Samsung NEXT Ventures. By type, the record holds 9 venture capital firms and 1 hedge fund. The later-stage round in Oct 2025 drew 43 investors.
About Beacon Biosignals
Developer of an artificial intelligence-based neurotechnology platform designed for accelerating the clinical development of therapeutics targeting brain health. The company's platform utilizes FDA-cleared headband devices to collect high-fidelity sleep electroencephalogram and applies AI algorithms to characterize brain function, detect novel biomarkers, enabling clinical research teams to optimize treatment impact.
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Founded
- 2019
- Employees
- 121
- Website
- beacon.bio/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.